Who We Are

Part of a Large Picture

We are Novartis Pharmaceuticals Corporation (NPC), a US affiliate of Basel, Switzerland-based Novartis AG, a world leader in offering medicines to protect health, cure disease and improve well-being.

Headquartered in Basel, Switzerland, Novartis Group companies employ more than 100,000 associates and operate in over 140 countries around the world.

Novartis Pharmaceuticals Corporation, headquartered on a 200-acre campus in East Hanover, NJ, employees 13,000 people at three sites in East Hanover and Florham Park, NJ, and Suffern, NY and in four sales regions throughout the country.

Improving People's Lives

Our products provide treatment for a broad range of disease areas:

• Cardiovascular & Metabolism
• Oncology & Hematology
• Neuroscience
• Respiratory
• Infectious Diseases, Transplantation & Immunology
• Bone, Urology, Gastroenterology, and Hormone Replacement Therapy
• Ophthalmology

Discovering What's Possible

Innovation is the heart of our research strategy. We aim to harness the latest advances in biomedical research and technology to develop new therapies with the potential to benefit millions of patients throughout the world. As a global leader, the Novartis Group invests $5.3 billion annually in worldwide research and development.

The Novartis Institutes for BioMedical Research (NIBR) continue to focus their efforts on tractable biological targets and selected disease areas with high unmet medical needs, striving to bring novel medicines rapidly to patients. To achieve this objective, we are intensifying our efforts to elucidate the function of specific human genes identified by the Human Genome Project. While structural blueprints for these genes are now available, in most cases the genes' primary role in the body and their potential involvement in disease remain unknown. "Functionalizing" the genome is a vast undertaking - one beyond the means and resources of any single company. Accordingly we have forged more than 400 collaborations in over 20 countries: 120 alliances with industry and 280 with academic centers.